Display options
Cite
Çetin G, Eşkazan AE, Ar MC, et al. Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turk J Haematol. 2014;31(4):374-80doi: 10.4274/tjh.2013.0004.
Çetin, G., Eşkazan, A. E., Ar, M. C., Aydın, �. �. �. �., Ferhanoğlu, B., Soysal, T., Başlar, Z., & Aydın, Y. (2014). Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish journal of haematology : official journal of Turkish Society of Haematology, 31(4), 374-80. https://doi.org/10.4274/tjh.2013.0004
Çetin, Güven, et al. "Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri." Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 31,4 (2014): 374-80. doi: https://doi.org/10.4274/tjh.2013.0004
Çetin G, Eşkazan AE, Ar MC, Aydın ŞÖ, Ferhanoğlu B, Soysal T, Başlar Z, Aydın Y. Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turk J Haematol. 2014 Dec 05;31(4):374-80. doi: 10.4274/tjh.2013.0004. PMID: 25541654; PMCID: PMC4454052.
Copy Download .nbib Format: NLM
Share it on

Turk J Haematol. 2014 Dec 05;31(4):374-80. doi: 10.4274/tjh.2013.0004.

Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Güven Çetin, Ahmet Emre Eşkazan, M Cem Ar, Şeniz Öngören Aydın, Burhan Ferhanoğlu, Teoman Soysal, Zafer Başlar, Yıldız Aydın

Affiliations

  1. Bezmialem Vak?f University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, ?stanbul, Turkey. E-ma-il: [email protected].

PMID: 25541654 PMCID: PMC4454052 DOI: 10.4274/tjh.2013.0004

Abstract

OBJECTIVE: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels.

MATERIALS AND METHODS: One hundred and thirteen patients with MM were included in the study. Patients were grouped according to the regimens they received, as follows: group 1, melphalan and prednisolone (MP); group 2, vincristine, adriablastin, and dexamethasone (VAD); group 3, thalidomide plus dexamethasone; and group 4, bortezomib plus dexamethasone. BALP levels were measured before treatment and at the third and sixth months of treatment. A fifth group consisted of patients in the post-treatment remission period at study entry (no-treatment group).

RESULTS: The BALP levels at the third and sixth months of the treatment were significantly higher than the pre-treatment levels in the bortezomib and the no-treatment groups, whereas no significant difference was observed in the MP, VAD, and thalidomide groups.

CONCLUSION: Considering that BALP is a surrogate marker of bone formation, our study suggests that bortezomib more efficiently leads to the improvement of bone disease in myeloma than other treatment options.

References

  1. Leukemia. 2005 Jun;19(6):1102-3 - PubMed
  2. Cancer Treat Rev. 2006;32 Suppl 1:15-9 - PubMed
  3. Br J Haematol. 1995 Jul;90(3):721-4 - PubMed
  4. Best Pract Res Clin Haematol. 2007 Dec;20(4):637-64 - PubMed
  5. J Clin Oncol. 2002 Nov 1;20(21):4319-23 - PubMed
  6. Cancer Res. 2001 Apr 1;61(7):3071-6 - PubMed
  7. N Engl J Med. 2004 Oct 28;351(18):1860-73 - PubMed
  8. Br J Haematol. 2005 Oct;131(1):71-3 - PubMed
  9. Int J Hematol. 2005 Oct;82(3):243-7 - PubMed
  10. Cancer. 1972 Aug;30(2):382-9 - PubMed
  11. Haematologica. 2001 Apr;86(4):394-8 - PubMed
  12. Mayo Clin Proc. 1975 Jan;50(1):29-40 - PubMed
  13. Eur J Haematol. 2000 Nov;65(5):331-6 - PubMed
  14. Eur J Haematol. 2000 Feb;64(2):121-9 - PubMed
  15. Blood. 2004 Mar 15;103(6):2291-8 - PubMed
  16. Blood. 2005 Nov 1;106(9):2977-81 - PubMed
  17. J Bone Miner Res. 2005 Mar;20(3):487-93 - PubMed
  18. Blood. 1983 Sep;62(3):572-7 - PubMed
  19. Ann Oncol. 2005 Aug;16(8):1223-31 - PubMed
  20. Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14 - PubMed
  21. Br J Haematol. 1997 Jun;97(3):641-8 - PubMed
  22. Ann Oncol. 2001 Jul;12(7):991-5 - PubMed
  23. J Clin Invest. 2003 Jun;111(11):1771-82 - PubMed
  24. Eur J Haematol. 2002 Nov-Dec;69(5-6):257-64 - PubMed
  25. N Engl J Med. 2003 Jun 26;348(26):2609-17 - PubMed
  26. Blood. 2003 Mar 15;101(6):2094-8 - PubMed
  27. N Engl J Med. 2008 Aug 28;359(9):906-17 - PubMed
  28. Leukemia. 2006 Sep;20(9):1467-73 - PubMed
  29. Blood. 2002 Jun 1;99(11):4079-86 - PubMed
  30. Leukemia. 2000 May;14(5):841-4 - PubMed
  31. N Engl J Med. 2005 Jun 16;352(24):2487-98 - PubMed
  32. Br J Haematol. 1998 Sep;102(5):1115-23 - PubMed
  33. Blood Cells Mol Dis. 2004 Mar-Apr;32(2):290-2 - PubMed
  34. Br J Haematol. 1999 Apr;105(1):127-30 - PubMed
  35. Best Pract Res Clin Haematol. 2005;18(4):653-72 - PubMed
  36. J Biol Chem. 2002 May 10;277(19):16639-47 - PubMed
  37. Blood. 1992 Aug 15;80(4):887-90 - PubMed
  38. Eur J Haematol. 1992 Oct;49(4):192-8 - PubMed
  39. Am J Hematol. 1990 Feb;33(2):86-9 - PubMed

Publication Types